Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 4/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775035 | 0.85 | L3MBTL1 (0.53) | L3MBTL1SMOTDP2TRPV1KDM4E | |
| SCHEMBL16041105 | 0.84 | HCRTR2 (0.43) | L3MBTL1HCRTR2SMOTRPV1KDM4E | |
| SCHEMBL30775080 | 0.82 | L3MBTL1 (0.49) | L3MBTL1HCRTR2S1PR4ALOX15HTT | |
| SCHEMBL607604 | 0.82 | L3MBTL1 (0.49) | L3MBTL1HCRTR2S1PR4ALOX15HTT | |
| SCHEMBL30775039 | 0.79 | L3MBTL1 (0.46) | L3MBTL1HCRTR2S1PR4KDM4EALDH1A1 | |
| SCHEMBL20773709 | 0.79 | L3MBTL1 (0.46) | L3MBTL1HCRTR2S1PR4KDM4EALDH1A1 | |
| SCHEMBL31347575 | 0.75 | L3MBTL1 (0.62) | L3MBTL1KDM4EPOLBALOX15HTT | |
| SCHEMBL128711 | 0.75 | L3MBTL1 (0.62) | L3MBTL1KDM4EPOLBALOX15HTT | |
| SCHEMBL15058045 | 0.75 | ALDH1A1 (0.49) | L3MBTL1KDM4EHTTALDH1A1HPGD | |
| SCHEMBL2372967 | 0.73 | NPSR1 (0.52) | L3MBTL1S1PR4KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9637496-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9475819-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, HTR7 | L3MBTL1 4584/4885HCRTR2 1/4885S1PR4 775/4885 |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | L3MBTL1 4852/4885HCRTR2 1/4885S1PR4 534/4885 |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY5R | L3MBTL1 4842/4885HCRTR2 1/4885S1PR4 519/4885 |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | L3MBTL1 4830/4885HCRTR2 1/4885S1PR4 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.